Right to Try for Individualized Treatments Act: New Path for Personalized DNA-Based Medicine Expands Access and Liability Shields

This bill significantly expands the existing 'Right to Try' framework to include custom-built medical treatments designed specifically for a single person’s genetic makeup. Under Section 2, the legislation moves beyond standard experimental drugs to authorize 'investigational individualized medical treatments'—biological products created based on a patient’s unique genomic profile, such as their DNA or gene products. To qualify, a patient must be diagnosed with a life-threatening or severely debilitating illness and have a physician certify that they have considered all approved options. While this opens a door for patients who have run out of traditional medical choices, it also grants manufacturers and doctors broad immunity from lawsuits if these highly experimental, one-of-a-kind treatments go wrong.

Custom Medicine for a Unique Profile

The core of this bill is the shift toward hyper-personalized care. Currently, experimental drugs in clinical trials are usually tested on large groups, but the 'investigational individualized medical treatments' defined here are bespoke. For example, if a patient has a rare form of cancer that hasn't responded to chemo, a lab could potentially engineer a treatment specifically for that patient’s genetic mutations. Under the new rules, an 'eligible patient' must provide 'additional informed consent,' which includes a written statement from their doctor explaining that conventional treatments are unlikely to help and detailing the specific risks of the custom-made drug. This ensures that while the treatment is cutting-edge, the patient acknowledges they are stepping into largely uncharted territory.

The Liability Shield and the Fine Print

One of the most significant changes is the extension of liability exemptions. Section 2 updates federal law to ensure that manufacturers and healthcare providers cannot be held liable for outcomes related to these individualized treatments, provided they follow the bill's certification rules. This is a major win for biotech companies, as it lowers the legal risk of providing unproven therapies. However, for the average person, this means that if a custom treatment causes unexpected harm, there is almost no legal recourse. Additionally, the bill doesn't force companies to provide these treatments; it simply allows them to do so. A manufacturer can still say no, even if a patient meets every criteria and has their doctor’s sign-off.

Real-World Hurdles and Gray Areas

While the bill aims to cut through red tape, it introduces some 'gray areas' in how patients qualify. The requirement that a patient has 'considered' approved options is softer than the previous standard of 'exhausting' all options, which could lead to people skipping traditional treatments for experimental ones sooner than expected. Furthermore, while the bill prohibits doctors from taking direct cash from manufacturers for certifying a patient, it doesn't address other professional ties or indirect incentives that might influence a recommendation. For families balancing the high stakes of a terminal diagnosis, this bill offers a glimmer of hope for a cure tailored to their DNA, but it requires them to trade away their right to sue and step into a role as a voluntary test subject for medicine that has never been tried on anyone else.